Shares of NeuroSense Therapeutics tumbled 11.6% to $1.76 on Monday even as broader markets traded higher, after the micro-cap biotech disclosed it would push back its planned Health Canada regulatory filing for PrimeC — its lead drug candidate for ALS — from December 2026 to March 2027, citing the addition of new biomarker data. NeuroSense Pushes Back Its Most Important Drug Filing by Three Months — Can Biomarker Data Offset the Cost of Lost Time?
Shares of NeuroSense Therapeutics slid 11.6% to $1.76 Monday while markets climbed, after the micro-cap biotech moved its planned Canadian drug application for PrimeC, a combination therapy for the fatal nerve disease ALS, from December 2026 to March 2027. The company says the delay will let it include newly analyzed biomarker data. For a company fighting to stay listed on Nasdaq and running on fumes financially, three months is not a trivial postponement.
• This Is the Second Time the Filing Has Slipped. Back in March 2026, NeuroSense rescheduled its pre-filing meeting with Health Canada to May, also to incorporate more data.
By September, the company was targeting a December 2026 submission. Now December has become March 2027. A pattern of delays — even well-reasoned ones — erodes confidence in a company whose stock has fallen roughly 25% in just the past five trading days.
• The Biomarker Results Look Encouraging, but They're Not a Cure for the Balance Sheet. The new analysis showed PrimeC reduced a marker of nerve-cell damage more than a placebo, especially in patients with better baseline function.
Health Canada raised no concerns about the revised timeline, and its standard review takes about 300 days after accepting a submission — pushing any potential approval well into 2028. Meanwhile, the company had just $231,000 in cash at June 30 with nearly $3 million in current liabilities, triggering a going-concern warning.
First-half R&D and administrative spending totaled roughly $3.4 million , meaning external funding is essential to survive, let alone file.
• A Nasdaq Delisting Hearing Looms in Eight Days. NeuroSense regained compliance with Nasdaq's $1.00 minimum share-price rule after a 1-for-20 reverse split, but remains below the exchange's $35 million minimum market-value threshold.
A hearing is set for November 10. Losing the Nasdaq listing would restrict institutional ownership and likely crush liquidity further.
• The Delay Weakens the Company's Biggest Near-Term Talking Point. NeuroSense estimates roughly 4,000 Canadians live with ALS, with about 1,000 diagnosed each year — a small but meaningful market. The expedited Canadian pathway offers faster access but depends on a strong data package. Pushing the filing back removes the one concrete catalyst management had been advertising to investors ahead of its Nasdaq hearing, leaving shareholders to weigh promising science against a precarious financial reality.